FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Apotex Corp.)

View source ↗

Summary

FDA approved Apotex Corp.'s supplemental application for risendronate sodium (a generic osteoporosis medication) under ANDA090877.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Paget Disease of Bone

Drugs mentioned

• RISENDRONATE SODIUM (risendronate sodium)

Snippet

SUPPL AP for RISEDRONATE SODIUM (RISEDRONATE SODIUM)